# Literature Review: Chitosan based bioactive materials in tissue engineering applications-A review.

*Generated on: 2025-12-26 18:25:27*
*Progress: [12/50]*
*Saved to: /Users/joanna/Desktop/Literature_Reviews/Chitosan_based_bioactive_materials_in_tissue_engineering_app_20251226_182527.md*
---

# Chitosan-Based Bioactive Materials in Tissue Engineering Applications: A Comprehensive Review

**Key Points**
*   **Material Significance:** Chitosan is a unique, naturally occurring cationic polysaccharide derived from chitin, valued for its biocompatibility, biodegradability, and intrinsic antimicrobial properties.
*   **Versatility:** It can be processed into various forms—hydrogels, scaffolds, nanofibers, and 3D-printed constructs—making it adaptable for bone, cartilage, skin, nerve, and cardiac tissue engineering.
*   **Recent Advances:** The field is shifting from static scaffolds to dynamic 4D-bioprinted structures that possess shape-memory capabilities, allowing implants to adapt to the physiological environment over time.
*   **Critical Challenges:** Despite its biological advantages, pure chitosan suffers from low mechanical strength and batch-to-batch variability, necessitating the development of composite materials (e.g., with graphene oxide or hydroxyapatite) to meet clinical requirements.
*   **Regulatory Status:** While chitosan hemostatic dressings are FDA-approved, advanced tissue engineering products face hurdles regarding standardization and classification as combination products.

---

## Abstract

Tissue engineering (TE) aims to restore, maintain, or improve tissue function through the use of porous scaffolds that mimic the extracellular matrix (ECM). Among natural polymers, chitosan—a deacetylated derivative of chitin—has emerged as a premier candidate due to its structural similarity to glycosaminoglycans, cationic nature, and tunable degradation profile. This systematic review provides a comprehensive analysis of chitosan-based bioactive materials, tracing their evolution from simple wound dressings to complex, 4D-bioprinted tissue constructs. We critically examine state-of-the-art fabrication techniques, including electrospinning and stimuli-responsive hydrogel formation. Detailed case studies across bone, cartilage, nerve, skin, and cardiac tissues highlight the material's efficacy and the necessity of composite formulations to overcome mechanical limitations. Finally, we address the translational challenges, including regulatory pathways and standardization, and propose future research directions focused on smart, shape-morphing implants.

## 1. Introduction

The field of tissue engineering and regenerative medicine (TERM) has witnessed a paradigm shift from replacing damaged tissues with inert synthetic materials to regenerating them using bioactive scaffolds that actively interact with cellular components [cite: 1, 2]. The ideal scaffold must be biocompatible, biodegradable, porous, and mechanically capable of supporting tissue growth while mimicking the native extracellular matrix (ECM) [cite: 3, 4].

Natural polymers have gained precedence over synthetic counterparts due to their superior bioactivity and lower immunogenicity. Chitosan, a linear polysaccharide composed of randomly distributed $\beta$-(1-4)-linked D-glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit), stands out as the only naturally occurring cationic polymer [cite: 5, 6]. Derived primarily from the exoskeletons of crustaceans (crabs, shrimp) and fungal cell walls, chitosan offers a unique combination of properties: it is hemostatic, mucoadhesive, antimicrobial, and capable of being chemically modified to suit specific physiological needs [cite: 7, 8, 9].

Despite these advantages, the application of chitosan in load-bearing tissues is historically limited by its poor mechanical strength and instability in physiological pH [cite: 10, 11]. This review aims to synthesize the vast body of literature on chitosan-based biomaterials, evaluating recent technological milestones such as 4D bioprinting and conductive nanocomposites that address these historical limitations.

## 2. Key Concepts and Definitions

### 2.1. Chitin vs. Chitosan
Chitin is the second most abundant polysaccharide in nature after cellulose. Chitosan is produced by the deacetylation of chitin. The distinction lies in the Degree of Deacetylation (DD); typically, when the DD is above 50-60%, the polymer becomes soluble in dilute acidic solutions and is termed chitosan [cite: 6, 12]. The DD and molecular weight (MW) are critical parameters that dictate the polymer's degradation rate, crystallinity, and biological response [cite: 3, 13].

### 2.2. Bioactivity and Cationic Nature
In the context of this review, "bioactive" refers to the material's ability to elicit a specific biological response at the interface of the material and the tissue. Chitosan's bioactivity is largely attributed to its primary amino groups ($-\text{NH}_2$), which protonate in acidic media ($-\text{NH}_3^+$). This positive charge allows chitosan to interact electrostatically with negatively charged components of the cell membrane (proteoglycans) and bacterial cell walls, facilitating cell adhesion and providing antimicrobial effects [cite: 6, 7, 10].

### 2.3. Biodegradability
Chitosan is degraded in vivo by enzymes such as lysozyme and chitinase into non-toxic oligosaccharides, which can be excreted or incorporated into metabolic pathways [cite: 7, 14]. The degradation rate is inversely proportional to the degree of crystallinity and deacetylation [cite: 3].

## 3. Historical Development and Milestones

The utilization of chitosan has evolved from waste management of shellfish byproducts to high-value biomedical applications.

*   **Early Milestones:** The first prominent milestones involved gene transfer applications and the development of non-viral vectors [cite: 15].
*   **Hemostasis Breakthroughs (2000s):** A significant clinical breakthrough was the FDA approval of HemCon® bandages (2003/2008), chitosan-based hemostatic dressings used extensively in combat casualty care to control severe bleeding [cite: 16, 17]. This established the safety profile of chitosan in acute settings.
*   **Nerve Conduits (2015):** The FDA approval of chitosan-based nerve conduits marked a transition from external wound care to internal tissue regeneration implants, validating its use in bridging peripheral nerve gaps [cite: 18, 19].
*   **Advanced Fabrication (2010s-Present):** The last decade has seen the integration of chitosan into 3D bioprinting and, more recently, 4D printing, where constructs change shape over time in response to stimuli (e.g., temperature or pH) [cite: 20, 21].

## 4. Current State-of-the-Art Methods and Techniques

To overcome chitosan's mechanical limitations and enhance its bioactivity, researchers employ advanced fabrication techniques.

### 4.1. Hydrogels and Injectable Systems
Hydrogels are 3D networks capable of holding large amounts of water, mimicking the soft tissue ECM.
*   **Thermosensitive Hydrogels:** Chitosan solutions mixed with $\beta$-glycerophosphate ($\beta$-GP) undergo a sol-gel transition at body temperature ($37^\circ\text{C}$). This allows for minimally invasive injection into irregular defects, such as cartilage or corneal injuries, where the liquid solidifies in situ [cite: 22, 23, 24].
*   **pH-Responsive Gels:** Utilizing chitosan's pH sensitivity, these gels swell or contract based on environmental acidity, useful for targeted drug delivery in tumor microenvironments [cite: 22, 25].

### 4.2. Electrospinning and Nanofibers
Electrospinning creates nanofibrous mats with high surface-area-to-volume ratios, closely resembling the fibrous architecture of native collagen. Chitosan is often blended with synthetic polymers like Poly(vinyl alcohol) (PVA) or Poly(ethylene oxide) (PEO) to improve spinnability. These nanofibers are particularly effective for skin and bone tissue engineering, promoting cell attachment and proliferation [cite: 11, 26, 27].

### 4.3. 3D and 4D Bioprinting
*   **3D Bioprinting:** Chitosan serves as a bioink, often combined with gelatin or alginate to improve printability. It allows for the fabrication of patient-specific scaffolds with precise pore architectures [cite: 20, 28].
*   **4D Bioprinting:** This represents the cutting edge of the field. By introducing "time" as the fourth dimension, 4D-printed chitosan constructs possess "shape memory." For example, a scaffold can be printed in a temporary shape for minimally invasive delivery and then expand or morph into its permanent functional shape upon exposure to physiological fluids or temperature changes [cite: 21, 29, 30].

## 5. Applications and Case Studies

### 5.1. Bone Tissue Engineering
Bone requires scaffolds with high mechanical strength and osteoconductivity.
*   **Challenges:** Pure chitosan is too weak for load-bearing bone defects [cite: 4].
*   **Composite Solutions:** The state-of-the-art involves Chitosan/Hydroxyapatite (CS/HAp) composites. Chitosan provides the organic matrix (mimicking collagen), while HAp mimics the mineral phase. These composites have shown to support osteoblast proliferation and mineralization [cite: 4, 31, 32].
*   **Recent Studies:** Research has demonstrated that incorporating bioactive nanoceramics (e.g., $\text{ZrO}_2$, $\text{SiO}_2$, $\text{TiO}_2$) into chitosan scaffolds significantly enhances mechanical integrity and osteogenic differentiation [cite: 2, 10].

### 5.2. Cartilage Tissue Engineering
Chitosan is structurally similar to glycosaminoglycans (GAGs) found in cartilage ECM, making it an intuitive choice for chondrogenesis.
*   **Hydrogel Applications:** Injectable chitosan hydrogels have been used to fill irregular cartilage defects. Recent studies (2024) utilizing 4D-printed chitosan thermosensitive gels loaded with limbal stem cells demonstrated significant repair in corneal and cartilaginous models due to uniform pore size and improved cell retention [cite: 23, 29].
*   **Hybrid Scaffolds:** Combinations of chitosan with silk fibroin have been shown to enhance mechanical properties while maintaining the chondrogenic phenotype of seeded mesenchymal stem cells (MSCs) [cite: 33].

### 5.3. Nerve Tissue Engineering
Peripheral nerve regeneration requires guidance conduits that are electrically conductive to facilitate signal transmission.
*   **Conductive Scaffolds:** A major advancement is the development of Chitosan/Graphene Oxide (CS/GO) composites. A 2025 study identified that a specific concentration of GO (between 6% and 9%) in chitosan scaffolds creates a percolation threshold, increasing conductivity by 52-fold and significantly enhancing neuronal cell viability and attachment [cite: 18, 34].
*   **Clinical Success:** Chitosan nerve tubes have received regulatory approval and have shown functional recovery comparable to autologous nerve grafts in bridging gaps up to 26 mm in human hands [cite: 19].

### 5.4. Skin and Wound Healing
Chitosan's hemostatic and antimicrobial properties make it ideal for wound dressings.
*   **Hemostasis:** The positive charge of chitosan attracts negatively charged red blood cells and platelets, inducing clotting independent of the normal coagulation cascade. This is the mechanism behind the HemCon patch [cite: 35, 36].
*   **Diabetic Wounds:** Recent animal studies have shown that chitosan-based dressings accelerate wound closure in diabetic models by reducing inflammation (lowering TNF-$\alpha$ levels) and promoting collagen deposition [cite: 24, 37].

### 5.5. Cardiac Tissue Engineering
The heart lacks intrinsic regenerative capacity, necessitating patches to support infarcted tissue.
*   **Current Approaches:** Chitosan patches loaded with stem cells (e.g., iPSC-derived cardiomyocytes) or bioactive secretomes have been applied to the epicardium in myocardial infarction models. These patches improve cell retention and prevent ventricular remodeling [cite: 38, 39].
*   **Conductivity Issues:** Similar to nerve tissue, cardiac applications benefit from conductive additives like gold nanoparticles or carbon nanotubes to synchronize electrical beating, addressing chitosan's inherent lack of conductivity [cite: 40, 41].

## 6. Challenges and Open Problems

Despite significant progress, several hurdles impede the widespread clinical translation of chitosan biomaterials.

### 6.1. Mechanical Limitations
Pure chitosan hydrogels and scaffolds often lack the mechanical toughness required for load-bearing applications (bone) or dynamic environments (heart). While crosslinking (e.g., with genipin) and composites improve strength, they can sometimes compromise biocompatibility or elasticity [cite: 42, 43].

### 6.2. Solubility and Processing
Chitosan is generally insoluble in neutral pH, requiring acidic solvents (e.g., acetic acid) for processing. Residual acid can be cytotoxic if not fully neutralized. Developing water-soluble chitosan derivatives (e.g., carboxymethyl chitosan) is an ongoing area of research but adds complexity and cost [cite: 7, 22].

### 6.3. Source Variability and Purification
Being a natural polymer derived from crustacean shells, chitosan is subject to batch-to-batch variability in molecular weight and deacetylation degree. Furthermore, purification is critical to remove allergenic proteins (tropomyosin) and endotoxins, which is a stringent requirement for regulatory approval [cite: 10, 16, 44].

### 6.4. Regulatory Hurdles
While chitosan itself is Generally Recognized As Safe (GRAS) for certain uses, tissue engineering products are often classified as "combination products" (biologic + device). This complicates the FDA approval process, requiring extensive data on the interaction between the chitosan scaffold and the biological component [cite: 44, 45].

## 7. Future Research Directions

### 7.1. 4D Bioprinting and Smart Materials
The future lies in 4D bioprinting, where chitosan scaffolds are programmed to change shape or function post-implantation. Research is focusing on "smart" hydrogels that can self-heal or release drugs in response to specific physiological triggers (e.g., pH drop in infection) [cite: 21, 46, 47].

### 7.2. Advanced Composites
The integration of nanomaterials such as graphene oxide, black phosphorus, and conductive polymers will continue to expand chitosan's utility in neural and cardiac engineering. Finding the optimal balance between conductivity and toxicity remains a key research priority [cite: 18, 34].

### 7.3. Standardization
To facilitate clinical translation, the field must move toward standardized sources of medical-grade chitosan (e.g., fungal sources to avoid shellfish allergens) and standardized characterization protocols (ASTM F2103) to ensure reproducibility [cite: 12, 48].

## 8. Conclusion

Chitosan has evolved from a simple biopolymer into a cornerstone of modern tissue engineering. Its unique cationic nature, coupled with its biodegradability and versatility, allows it to serve as a scaffold for bone, cartilage, nerve, skin, and cardiac repair. While mechanical limitations and source variability present ongoing challenges, the advent of nanotechnology and 4D bioprinting is opening new frontiers. The development of smart, shape-morphing chitosan constructs and conductive nanocomposites represents the next generation of bioactive materials, promising to bridge the gap between laboratory research and clinical regenerative therapies.

## 9. References

[cite: 15] [cite: 15] Historical background of chitosan.
[cite: 7] [cite: 7] Chitosan: A unique natural polysaccharide for tissue engineering.
[cite: 28] [cite: 28] Chitosan in 3D printing and bio-ink.
[cite: 3] [cite: 3] Chitosan properties: Biocompatibility and biodegradability.
[cite: 8] [cite: 8] Progress in Chitosan-Based Biomaterials.
[cite: 49] [cite: 1] Application of Chitosan-Based Polysaccharide Biomaterials.
[cite: 1] [cite: 2] Chitosan-based bioactive materials in tissue engineering.
[cite: 2] [cite: 9] Chitosan: A natural biopolymer for regenerative medicine.
[cite: 9] [cite: 10] Chitosan-based formulations for tissue engineering.
[cite: 10] [cite: 14] Chitosan biomaterials for tissue regeneration.
[cite: 50] [cite: 51] Chitosan scaffolds for bone tissue engineering.
[cite: 14] [cite: 4] Chitosan scaffolds for bone regeneration.
[cite: 52] [cite: 13] Chitosan as a Biomaterial: Structure and Properties.
[cite: 51] [cite: 5] Advantages of Chitosan as a Biomaterial.
[cite: 4] [cite: 6] Chitosan and Its Derivatives in Regenerative Medicine.
[cite: 53] [cite: 22] Recent advances in chitosan hydrogels.
[cite: 13] [cite: 26] Chitosan-based electrospun nanofibers for bone TE.
[cite: 5] [cite: 31] Chitosan-based scaffolds for bone tissue engineering.
[cite: 54] [cite: 32] Critical Overview on Pure Chitosan-based Scaffolds.
[cite: 6] [cite: 44] Regulatory challenges: FDA and EMA guidelines.
[cite: 55] [cite: 45] Regulatory status of chitosan.
[cite: 22] [cite: 16] Safety of HemCon bandages.
[cite: 56] [cite: 48] ASTM Guide for Chitosan Salts.
[cite: 57] [cite: 12] ASTM Test Method for Degree of Deacetylation.
[cite: 25] [cite: 10] Limitations and challenges in chitosan research.
[cite: 26] [cite: 11] Advances and challenges in chitosan nanocomposites.
[cite: 58] [cite: 59] Chitosan scaffolds for cartilage regeneration (2025).
[cite: 60] [cite: 61] Chitosan wound dressings in animal models.
[cite: 31] [cite: 37] Chitosan wound dressing clinical/animal studies.
[cite: 32] [cite: 38] Chitosan cardiac patch for myocardial infarction.
[cite: 44] [cite: 39] Secretome-enriched chitosan hydrogel for cardiac repair.
[cite: 45] [cite: 40] Chitosan scaffolds for cardiovascular regenerative therapy.
[cite: 16] [cite: 18] Conductive chitosan/graphene oxide scaffolds for nerve regeneration.
[cite: 48] [cite: 62] Chitosan in cardiac tissue engineering.
[cite: 12] [cite: 41] Alginate/chitosan scaffolds for cardiac TE.
[cite: 10] [cite: 20] Chitosan in 3D/4D bioprinting.
[cite: 63] [cite: 46] 3D/4D printing of chitosan for wound healing.
[cite: 64] [cite: 29] 4D-printed chitosan carrier for corneal repair.
[cite: 11] [cite: 30] 4D-bioprinting and shape memory polymers.
[cite: 14] [cite: 21] 4D bioprinting of self-healing hydrogels.
[cite: 65] [cite: 47] Smart biomaterials for 4D bioprinting.
[cite: 66] [cite: 67] Graphene oxide-composited chitosan for spinal cord injury.
[cite: 68] [cite: 18] Chitosan-Graphene Oxide scaffolds (2025).
[cite: 59] [cite: 34] Conductive Chitosan-Graphene Oxide Scaffold.
[cite: 69] [cite: 23] Chitosan thermosensitive gel for corneal repair.
[cite: 70] [cite: 24] 4D-CTH for diabetic corneal epithelium injury.
[cite: 71] [cite: 72] FDA approved nerve guidance conduits.
[cite: 61] [cite: 19] Clinical outcomes of chitosan nerve conduits.
[cite: 73] [cite: 35] HemCon Bandage product description.
[cite: 74] [cite: 17] HemCon dressing in combat operations.
[cite: 37] [cite: 36] HemCon Patch Pro and mechanism.
[cite: 75] [cite: 76] Chitosan/silk fibroin patches for cardiac repair.
[cite: 38] [cite: 27] CS/SF patches for myocardial infarction.
[cite: 39] [cite: 33] Chitosan/Silk Fibroin Hydrogels and Scaffolds.
[cite: 77] [cite: 42] Mechanical properties improvement strategies.
[cite: 40] [cite: 25] Tailoring chitosan hydrogel properties.

**Sources:**
1. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFAnp-7YT6U6q7tLxUql4mQkbbljq0pgO3B1UX-63qXwmzhidGFriT55G9woUkRzmyZxdgDhww797WDGfXhyMjkzeUYdcPDOmw8quV-OOA185ZDGJ7Gi0J9cfqpN_RpMWiPhQoCwSEGQdUrsF22FFU3HgFSLoMBd8lPM2JBiOzRFvzPx3i-wmcclm2SA7wJX96pONkKk6sXzohssgvDxv0NFD-Ku4Lg0PMbtGe1InMaLs10a18PoE01tVlv_eB3yMTRxlS66v26CIbwXln8mThN1C3r5G-1fHWVdvinKQ5VNYPn_Q4=)
2. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF1Guby4wtlG-Zupwp5TMQn1J4iGB1kfHfSq3vC8-VBnKwfrhQTmk7yku3iQtwo9CJOnck-xTZ8G88RxXdGuLqSfu4lI7-CnefYMVqI23EaAtBlNBPW-vFaGhE2mbGxioNwjEsQ6DlC)
3. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFwxx1X8uE7glvgzKJX6tD8DwNNlWMFc3m9KmCFC1SUANhZj4KptXlEKfLXjL4D0jJcZGT4L-INQpifZDpvAZoDa8w3PrEU9TSdWufAH4whUZ070dEuuq0yfKBhv2H2jkDn0_8U_ENsgA==)
4. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHVAlKM3NVKQ4wN810uPR9Mq83r4dBBvudOBu_WLGEqmNniNUnMrIIM5EVyjO_uPm9NTj7JkyO-3q9g9KGaVQzJDkhOFQJmfvproUB2LoYBbur5ogf_FapoInNi_vYv0Q==)
5. [youtube.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEIW8wmMs3vAtM2SuerRXcNT6lmtLEeFIZ7zQmbuVDpbCffcJl_NsUm5U77rswrXZ7_Prv4lEKM4XK_LM0wwvGIDncv4MpxqzL38twEZmeAJOHrfH6jVztVqA22rXbuIiv9)
6. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGYWdgKjHXa_H6CBiscakHUa8EgvMRFAiPJGJl8hfQNhNsx_uv5PJstvAMn7-LG6_F0OvV4_mB7yqOImeE4ZiDWm0Hxa42Ooi4Yl4bvK35b2iDbRcV9eaINsGF7oA2EDKvxqMfFd9xf)
7. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHKG9jnH2wRAszrIQMmkAOKsiFIyNY1ZrU5RIbrjgMDPOP9mGAeQs6QoZdAhc0j49e3rPPgRytAqQu2jwxCdbMNXcKF7i8yDkkeFprsB3zU0b2GSrXGB1AEiJ4BlA==)
8. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGnLrPwQAtPC4cEeVT3cQ_QeRGObMxrHIV7_ATeWN25v2DqO0ma5CL4qh1PXAUVSYLqljGHu3hYaIcU7nOoIiyp7v_yrubk_8F8hHlbLBCkl1tv0MyJtnZnfp4dYjn07k-eQmn-1JI35Q0j4PQ6-G9Ek9bT3ivqAWJhU-Cm0VJt2ZhXV3IBGtSzWUjZxmaTTNsdsgD7uX2DgwoMNRNh78SkKrEK6XO9NUkmNymiMFK3VDWZ4jrgtK2T0yuTfmIHb-y8KSpfiyS_qBnNIJ4jDJ-rSC9cM2o=)
9. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGtR_LIai8SugczXdpfeyEpOZ7-UNlwnIbaxtHg4oVMTK8DtP0Y6C1IjfyqLDAx-LypCVmKsc_Dr4pnYG8zO7KF6rCmByDo8JM57KdlJHybbjLOc1dao1ccwZEB_edle96_j-6uNQorIw==)
10. [rsc.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFO8rIIk2CRiJOXXByrytKo4cFNBbuJ9sVDwy_1YMgBTWJjJFNT7PuedjEPEUYB4_8l5nGsb6Z3I2UVSZgWNTZ4Vhn11_PV3650xS16ECpjCBh3Etm7_YS5Qz3GL6TLhHYxxuljUszCE4E9aG4wXknsSixyjg==)
11. [scispace.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGuBko2vaAkL3mGL6q0-UAT74_VbphfYNCO414M1EhJRDW4T5dncHuf0rdtUnXXxJZR_9EMiX3x_LkkY0ql7oofFCvv7xFGknWaliN4A44kfWgcr_jSi3A78bLEf-3pA_eBCr9eoKkhbA8TwVNjfMP1i9ZCPXGZdXt1QJaH8hCF4LsVzfEI50VblO6-bmLoImkJ)
12. [fda.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGiTzCEkKoNjrIjtJCd5XJdbMdEtTA1ZVLQM8Gx6tk0QJw5FUF2POwnwiOIuvTzUGD-5RiUbc9S17bt-tLESylFlmXa7n4dVqUQ1mWXLdtT6V0GCnnI5PHtt6HnYo6UzGd9iAa1XNng-AE2ax5dcgcNzFy3mCyt3Ug8yYCmk-eY_jTUSyVUPRj0tFrEc6aGuka9YRklhjYjwCSqo8QOeoiy3g==)
13. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFpfuQdxEWpUeG6J-ujOyfnW7867Xt7Ff4NQqQeCcuDW5aLCpZY-679_-7GW5mXKO4TGfls8kwMLOGaIKaPglBHfeZ5Hp-S2Q30UBnnVEeQPEKuIrAboW8nYJFtIywCu0kwmQVLolfW9HZZ26HvCXYgQYsb6tX87VcN862YtUB_5u76PX5BYsMLv0WSDpUJK6kt9BBuv-F6EQ43xQ9RtHgqMvsTN9mCdMMXUfm5-vxf4GH8_utImRkQ7VKl_t2CJ-foLEEmLK6STmjzXau-92lDjQ==)
14. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFTmOTJ6gSfk9sP6DbfP4AdVRUIqvmGgYJ0hzHuqaLVfGbFWZMPDVI6ocZrhE4JIuFvM6UB6rdUJSterjidAHQ8sRg77SmVWR5rjdRIdGolRDSNpEncYYPwnYzr1d1Gjk9oIBvNdaNBKw==)
15. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFudk6_rib92eZe2-b6w_woWQlR6Xak_-xPK2BLz-OMieJnd1j-Xsov6Wx-nD0-ht1RsoCh47zfOqRPPEwEzbGvljLVlAP6F1dWnoD4ccv8eLFuaNIG8trnXjyPd_6BWFvm5vfQe83JnpYyV1E-QbQiF98vOd2bbz-pgXynl67X9I_xIDP7snftZog=)
16. [food.gov.uk](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFTG100zWOS7HaaLLDXDELANvHZrKVyfZfvlU7W9bVIF-ptSv4-QuDbXlkJLBHtm-3UUGQ5YzMe1mo9mA2UewV5X8lLVogEcQZZiBcHj530evfETkHVQukp0VOUW2Z2Lw4doj2DbMWyiewrJz-Bxp9AbtQgjoTM3u9Im10CdtGxx2XqMdQ=)
17. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE3R96XVhsHJtVX4RaMO5FqfaLeY1xOfTUApr2shCIpKsAQiFdLRR0KS9HUs_2dX_LHh3MM1xKlJyfRJFbfn1SYwvfHuojJXk-w0TQT_2XF0fSzu56moj_n8jjebhXli-2YKlRggllP9WneajufCWxfBSuiRhfGOoJBfcS3Whj2BDdIsys2ifKlsGRzZsKajx7-dFYUB_RKm_j1_SY1IDN0djvPKU4VfeNYJjdC5d9EToS3XY7N5yOSiQyUPr3zP4sn8JD8usl_dbKP)
18. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGY0e9oNTWOJOP7_yxBnNVIiaERejK33H3CTyQH95tzmd2eR62T7lkR7qIqSrUnOLosY7fZu8I5N9DsmvF4z-ZErJzVVTo1yUHwiVjXSoOhXDYGJoIbHzhTn35-_6GnUA==)
19. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGj-p39dTcz4P6m0UYdvwltQ8oVi7RgZGTq8_bnMEiBP_6I0cLm-PTcyHUl5prCWIFrK-SJhAL0Z13xU5n02aG_WpwUD_MTGBN8hsPjARs-B7r925g9iEvsbNi-Jj1EDiDZS6d9ys9Q)
20. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF3qHyYWi-OlPr2aY26s88Hp4oqr2ss9j9-jAUtQXmh6alEc9TKDQtmxHkAgSXDpERwsCcnABESiodq-9oF2JAD1ycLmOhZqXxh_rbIooZmEHmvQv9UlZsAjp6w6wf7HENZveDb-9EgyaEKplozzGmRaFi6iBxdVZ9Ibm0yrI96AsniZuL3hbo7_bCUESPDFaJgO0FXv2WeweQ8xw3UTWerqJdosJmQtJrpFdP8QABlLriN25_WnMiDBqYwjWz0rGP3Fw8X8C_fzp4bSFHS1DT0MA==)
21. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFnY1C4wEC44NL2If5jIsQcx9_L3RCm9tUnIVZa7exvpeCsWFH_I9TJuhXnSjSMlPJvpqo-laAI09JRthN6LJqJFeAroEuoqbbxX6dmTODjck1aW5HF1orYWcu4Os1UUA==)
22. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGkJMXG5U_G3moJtDwJFBoyTxWQ-K1LG3i2dFqGcRDWZuoeHEt2sZ8qsaObZGePz3JTJAkZDfDpVoEuQvm2ac5z9iAnOHB-GQKjLV4RdRVpmTGuAFpIcMfFRAxQcDvKdz1E4djF4c-K7ZkAdShvODaHmFn-Kvw8mLCZlbXh0gUlhilkKI0VjgbNBOc98j9aszr1noMA5D3GNQq2rg5YzLcoYoUZ)
23. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEfvKcNoC4G16pJJnxo85kedimAe0DBgIp1ICualSpkBdPXCE5weAodorw87gdLujNjdlak4f5iS0tQSV7oIQxvM5IAmf-0ty0sC-DzgLZ8HWl4p1VhFI4IhbIqU3BQ4ndjwMCOWBpXtg==)
24. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFLbSMXPIp5gzpXO-vaJmcuKb4ZYE5jXRS6OCRr2c2T77zYChFAdXGVTOvVDdl-ILmi3iyRHORfD-iSj-_VIH9FcnOKbwNxNeFWXJEElVAuaxiKm_BKyn-s0L7yWI0qBKZjRuMYgiHAKVnx99kR9zCqEPMgC_0-8JORxTOpiAcJ8k3NrQe5Uo_0XKmBpt1i)
25. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF5hwFsa44-rJlibzfHJVCoIVsQg3ahWTHWUfydT3gRreFzGUyJCbMQX6hDcaX50pR1oxF5riplWMdmBuvK-mbPg4lx2y2_QFGKjifDDtGIygnl0soPawwfdfTXS6R3Hrvsjh2llmPQoA==)
26. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHU_wLGyU9a2L1o4n_nTg2KcHRQim1jhd3-wcXhpeTgyC4VJbhOL-4ZwnKlrQL8E8Ij7n1ZXVkTdQPUvzIqIFu9S3HDBPMllEmdFujjjfLnW-09YsmhcCHM2Qw7aLc=)
27. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGcpIkBz3-ZsWmyHpYt-DPuTjlCXP1lczl0nOem7Sb4kqEdPKdc5WicsR5V0HnW8WIjpLW4dmZ2yXXlK4zyVFYVN6fF5yiBT8KuKB5XYRU1S2JVu80N6XYT66sV4HyLVg==)
28. [encyclopedia.pub](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQENKZF5Mf2Fu8vcbMAGXq1zBEKPGKQ4Vyt8uCuSnnHa2SwzwE7BfqzIskTSdju1ksm0d8dN0AXnxUYR-UKJ5louKTZIJgwhcdPA7nYwZL_23tP4AtszjtRs2IU=)
29. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGxZUBySwenEu2_NVfmscepNDMFdfSQ7etMhBM3v625OKaW3NVoXWXlvFGxahmU0my0yQUTi9SPesq9PZ5YneTAynE8truKjbDUQOHQPpyxVUEpW09p6IXRZ5f698UeEg==)
30. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH8roBK0dGSA8E3SbZBB5pNrCo-1A3aEAK2YrBrrAgDja-ZWb8iXBvYHMqw9w9LC3vKxkoBwkomvYZDKHpoYPYyBtrI9wWM-fAIZXboOeToYoGVenBXAvKfX81ZXw==)
31. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHcuu-3in1GOzLb4-og116WCjLX8EYZR_n5VpQGwCo_w8kvb-5K9VgE0UMUvMD0DSN_kZCYnofZ88JQ_wKZESqTJj1QpJUiZUDpPtKd7e2ouY7CpPcWPYYknNPSceYNlDCIorwa8lsP)
32. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHutbwVc6Jae841nQoAysUXEhENrYI5R-kcBHsK8XFoTkUnXRzYQJ8xMRNBfy_aZDliqrw13tMHsIFe-VcgGriIfp8VBkjVj8CR2XDNZoQ2ADWJ6TnZIwPbUYI2V39jbHkoAnKv_GyOHsIZ8d-4VEFBAzFr7Jszmzs8z8m8lzrLtRboWumEnzTQuvQsXI9kNtclaGEOKMGj_8LFoM50ulffcBKZd8VBN8ubJ3oMjIlINQ-TDgTQcZ-0jzpTnrYBp9evU5P4mbLMVxznaUfDfMNY9MQc_jY7gw==)
33. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQET5xUJrGJOPD51zjQUErT_SUFym586_4Wv4ovewp0q5wFeaqvQ_bzaorJPegSIsvzNl_x85WCPO3anpSwMiTa7YN23_RcVP85FpDKArhsSoX6J9K4D3S3x0ASfgSC0)
34. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHZEotppuz1qxifVuPY3A6prdBtPuhToYvVt0h7I8v_1B8pymuBYIPSQIpKGuyEJGPUK4YOuTLtPz7ZIruBLemTzD6hCdM1FBCITGck_g2ChJXCcCMikWEgxlPEggjU1EgBTe389PC4JoAg2KWgRSMgMBj7DiJJuqTbDnlA0POzA8ZqKXb1GFiL30hti7IqH_YFdeyl8ho98xTviJE7-HCC9M4tL_WbckcQ3h3qicPlCkvDqvVt-xwfdzAzJly9PoIj_Po1k52zsNNZPu22Wg==)
35. [mermaidmedical.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE9Ba5OjVClCFeUQaryH9QRekruHFZO-Cu_nAd6Rzs0dUJYB0_O4vSi5UqpC5Cvc1ygOG4S-MFnwqv4dJ7IR941sI94v3JJ0fpjz7EYxF_o3lCZoME5cYxCJi9HQnq62zWysvLpdg==)
36. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGDUkwZBxcGftxx-j3FJyvjZiLPyStomGFUjCancJULMRXAd4y3SkVCm_q6zlzCNPZ_dLkBXwf2-VH03i5jUTgNsARcfNc-NEqXpl8-6ZDgzdMy5W-zcoRxMzux11ZQGhGA22FYFvwqQQ==)
37. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFd4ZCBHp2TZvQTm30kLO33zJhBEyDei9thXWQjk_Ip-QqKxHt8RQxVFd37MRmWnxHH4y38EByheECPo7wA-ukOmzHr2EfNVdBbPfkpcOzz5sY1rUu_aaxd1aV9nH_6p-nzX6rhOBsxBw==)
38. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEMQPxSmAg6XNp8AEDljIhgqtg-pNxAJS-q-u2vQd8rOCEHGb2d5BLpQxW_pHgsh0U8zR9wbHhUAd3UW9XJIv5aTUvMSI6c64LYm5J3tXBe3AFllcXLGlok1AKRwRejcDIKFXQyucQRDfjGAEg8KBCpRiuwtuGovGXcnSD63hiY-ESi58xy4qlKolfb-ZQp76Td2hL_ZEVWWSurQPO0UfvM6pwWGKHVUkmGOxAS_n6M-dy8pUEHSoXoz-zF9Eux8IGpfy3sf-VraFLK0Pk=)
39. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF6fE7jAO156dhLU1hRJDdVKzQ1hpd1DsCYm0ClIgFC3FSN2eC_2StqsDMXC8queIfO_SQUZyCgQcDTK9mJVW320g6Ip8QEvmGXoEIuEz2ZYnSfE25ir8v0utr0qIpfNQ==)
40. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE16qkCFKZOzLDnNllLkYYdROB7-VJEtDMnFTk3Dsvt9nnhdH5H_F6v0tTB4OAMTrPid3Fj-2ow6fznrnkhkGerbizIABtREq_RcOofJM2swAQ4x4g3aC7_4wi5qNlk)
41. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG2hh7oujjaOMm1QLsMFsGTrCwcT5UE8dS0T7jIvbzHkHs1QrVZx5ymLgJToN1YL3gEWa4o7ktCv2WuzcHuztaK-FgL7A_lB949JTftYYahL_0cWyp73n59rpmNOqjkjg==)
42. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHv8UE8moFjO4qEmv61GMH_sWfMI_SwMDTvE8bHiCO5d-xOrwxpZMFhVO7sdhXbcpJ3IOuBkpkBLlbK7DMOh8iPdiEYnj94aUJ8m1PyTf-xNsfr6SXvHcMG6K9pP-AJoN-cc2LtM6mSsQ==)
43. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGF2CsUJXf_TXB7NyOsXbO8-sD9R9ipvMCi-F6vxI2dQP2ZyjLId2h4bzxa294Sa3VipQs4nBC64o2gApi7xECcWpZEmmJQQQf5sqFe43Pzbr5cxNZ5bP1PYwu6xLquC7jiz60GWopviQ==)
44. [entoplast.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEeEjtBd2zc3r6AtwJWvjoELHYtrFC2iJVgEa2dJbEqfSV4EgizygVAToSocnnvGIgwsXGdwb9myiDIrgG03D3cCLhd_I8GbelK3gIzvLEVoGDAh0bHwBl-o3zJluGql_e9U4nO626yJhpTWqqH45otRVEiFVv0-R67b4CQvcCezvgV9InFfBy5mkvNgk2Sn-E-oExL8LWR1Q==)
45. [cd-bioparticles.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHoGV7ksDS77RqvHym3dOhdfwOLZjTNfD8IAQsbn2s9QXX86GmtYkJHibHJGzI_Huvzr1kY_Za7wOBvBorFFrlagjUzoqGLyPjYB1oCMHqN5YRspu_-SZQYiawUjtwvxhUWyV_3njZflRJZllmseDwfOYAthdFkXRx6c_kyPkaAzcSz_RUX-N5YaW1yyFBk-o98PfMAOWph6Fjck6rN68_EWqyVcWVRUMyKaDYmaI4=)
46. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQERbk17ZE-EeAh3UAMdIBppvy3MVEf78TCAx_FXN2xbPv6y9bSCvYBrGe6ZPthcPyYmWR1hSHG7xXWium2LodKD3Zl9F0dgPspA0yb7gSU7FYw2KSQtiqu6Z3c9G_l3SbyXTH1uAvUARFq4tdhXLK1qkmsJnEFN6br4v9nd18MrZv1aRAaRAyUuDySX26qNDpbYXvIthIS63dBYaREr19UIFO2vz6pFuf5EAsTL-GytuwsztCNfafgOl_SGbl0yPxVfcwnCLTrku68EqBB0p3t2ss3o_4UKT8OmOLMQ3o7cQcLnpEhMYxIjjngn5K9VnDmCTm-Y3yO5dSfuhSlXq086zxJkxR5qqAunOY9_vexnZ4M_OcvAC1znPlDF_hdns1gu4V0=)
47. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGZhZAQmD07MXxcWLLN83hwyNCMY8tFuIUmZ9rvCdnG_5NgtKt7ygDdaN3CA8-tZH1rjZPnaKBYtwj3CCRwopTi1Fofz_MKql3rlM1NOtwIfc6yeQ2XshuGz1eR7xEExaTZAc5Qw7Tb3Q==)
48. [fda.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwh-epkNrgBq5iMZAsQXfE2uIJTR4qwbC_k3YI32FxU_mO5csZFLc4Iw9v4cER1WRm3EMAENsvSkMVl0j-YKtnfWm12QNO1YSHK3_C0kx_slkFeh2zLlfPMuTVjdqsZo8ZIUkN_MpLqtHTmwbtqKrD-LMcX1sjfKB-Cb7KNLV5M18IJ0rBjxEbNbSf0V5RKSI11uoJjdOQS5oSPLHpeElv1g==)
49. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGvy_GwQ4ZhbpvmCeV23YChyr5GBVNQkC1n3y44BGRF-rsSr3bJ_su0SzgpOuQoBhvzHUkcafjtOvNATuanp9f2ySHJwx8Dbgfouyv1YiKAQRTqBC_ma5RNOboWci7R8TISEuXp_Zvc6UmxyB5oqFxmnr7DTCJRgZ6V2Wr7TX9nobWyEazlC61Cl97y4bjXIKpYmUF1sSVR3xLwiE2IlxChNEUJTPjF7QfKEOfDVT1oi9Uk1k3S1-SQ)
50. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEBjsRiuIigKeXH8Cp2Ij2eB27IQ8SqxZscMKt-A316KXJgAodshehnGgll85pKev2boNQiKUh1_Fn1hspSoCk7O-JDsbh6AfhIRO-dUaUWMIYxaaXuKt3rSvZOGJyPgQ==)
51. [rsc.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE1beFrEhtIiY0s-qTCiAebBGi7Wy0rjkErg2tlh1LSgM5BMmNDMcgesJfgapXgCSJ6EV2BeUOftu48LLTjPPo2uBHvUIlOzis2lRKnwNa_ApyJOSY9rXz3uBGMgWbP6OZ0TaYg3piRqM391UZm4q_kEEqgV8Mlog==)
52. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGUGGtD7Pcc2U4WviJN7dH5l4mtZdvUIehavZwWYXjuz9jp2xrA0f4uHNVFnKzjXBkgNaNCafVhbGtZXv73cXWXZtfzrnCC2ENauK8SqgRy9iyzLCodHdeLkyC246nVidG0D9KO-hkl)
53. [scispace.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFzAobPC6SGv5XmOtfJxpyc5zIq46wbikn2MCff69eoPwxeK1znEJ7-acZkti91atncoqFaWfvsYqzaccETb3wM4WoJ7wdoWjtr0n38Y-zuNxSPolw3gB0fGyM5sqIjzZ_EaUmKQ09B_EumxYXQ7Lbtyct_OTG2iH7xQCGDisFU5Xg7moEqJRSTk0ih3tth55YriVNkxLM=)
54. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEK6QlZxBoslUiVDH6P-DNIpxAyB09i_nWcN9JtiF6eVL_39lEaAOhaN0qiiP4sqbiOeKlXj2uPkulYlxsOYrSRfA7mz1TL-mBD2VPoJufiXzH_xJkIJnAN77HclA==)
55. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEW0SAJGfYZXf9995dNBAXMZ2lvzTgiT5SasgiM3HkOyxC_YVoSbftGReEPKtUlqP4Zi-OH86DKZGLiZ0pi2ldoNuU6tV7bKKU5kjfRnoaBfVTUrcpwMNLucbwFvpI=)
56. [semanticscholar.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE8puM_3PbVyyiqnhvZVJRdsQSXrQscQbQ044rrADxcWnPT9_IZsuREJorIZSAb_9Q3C3Y8YFJ6IxlSn2D9mgrsNTBuz108StW8JcT7wu8cj2jlVwfwhPZLizDsSM8LOU60EZNsFaIvpDNqClbZ7XnWA7pOD7O5SDEU7-ckOIoyeO7cphxgRPTVHQJtOApKfmxPsfWrkKIUTyJ6kAR-_OfEBdCz7UXJrp-baaDdqNM849e4QE1pDrURl1b7FfxN9qIHba7BwShUYj4J)
57. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQExzPZe2h8ExEU8njsGtJCNLerNlkvZYN5keHYK3VYbDMEHfToYYO9SMPQvh93kK3SwkMuc9Q8pO6_S4onDvDle3NWC1MWO9GbxMZJZMQatVMvZ5bogmedI8PVvCiFelzg1U7-Q1wHIHA==)
58. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH-1DkDBYTiTSLWbpp3zec9l3h4wbvpYh7TsUGFTItNEASknfe9OTDlA_PTYj2CmMfuQaCWG00DRE7VvLy0P0xNdZo9dcymp7-zTRL12mAkyd9J8Q8E25ZbECW6nHecPQ==)
59. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEbL7QezJLsb9w6UHL_hf0UzmQ24lVZfVHi0F_12kESClrOS2NUV5K76mKDOXa5uZyHLM8otUivfAe3lfj51OltpiGwXMS7tbEfUGINgFJyLcnWboE8pJl1hKM6bWm-JOvDlPXnuWnu2BIKTyxtFJuVOxBTgg8WFGY7wcUYgIn_whcIvrmgUrLlU9-YNgsWw9iSduJ8W0HiPFRhrd-R5BXCpd5LvpyLahs5p3H-rYptaEVR-ZX6WM2NX9cPG5bPtv0zDRF2ajBdQkHKTbk0Jusy-FPFL88ky91wiXrj2Q2Zk_lt6i9YD68qSZJQxCZ0I3iaitj0lt62-Igr)
60. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEAqpLc7lpnPMn71jnzVnKsT-nIOwAH6cZ1JgoLwvdWE9LjnlqLEkR8UdIpWAqUXNW0qXsfewpQmuvdgbE1vFgu3m8v9ofZUJ3dQ4ZXMoMssX3ztNMA_kZTOiry7Uo79g==)
61. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEB3K8EBqrm1YGnbldDtORGNXxGzQ5FUqkmcNwhgWAIQBPKh84qw2OrqgnGikdZnLidjsImCdHUGoD3TmhllyahDM6vz2e3nJjHQvKe_DWWHZBPa2NQzo5Sv1DVZqQDNAoCLpFUn08Z4wn2qnQWF0seMfqySuhNXo0ce8cZjL1Ex31u98jBB-O9r_WLkR7NhPrd3gD63VsFM12yzWsB18sEAnlAwsbJBu-CFc2i)
62. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF-HQbtBRAnOoUvuiIA6_fWwfK6aAHQMX8KKup2azWue5FK2MZgsOhC8JwgMv6PjTuINMTgQgK12pPvxcB09utc2SFkmmeXR_nNYzA5B-7Ygqg0XG6XEFNFbNqgpMddPd01aS4n15af)
63. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH-5pyys_ZVxsdjP_eyorJnNXIXWE2yOiha36LMBHaS_onZrNpOV41fFTRhTps43wUrCLLtw9vAjohPglqvwfLHcmWPZ_7tvE4DZpR7QyapIsW33M5y9fJezUR43W3uzA==)
64. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGXaGkmmikqfKpQ_hsJGM2MmpDOYKMWZwD4XJrE9DSErpaMNh-BboeINRu6D1sF9np0cw3FLr6P_eVUMPTWPlPbM8E1a_GoP5Vy2BTZCW1XEKQEhCogDUes8UqWGR9ArLRfivivSYY2mcwGFU4syHDflXShhk_90gXyNTAab5urXKfPukvz0lDwY-BgU3mz9OMFMZI3Ux4wYzbGarOE_Gt2CRe-GLHwcFYAY7PlPjw3EMKVV01KTsbw0kc_kcqf0fQrHbiYhTxQ7w4bXVQYTA7tLDVGyk9nyFSyM3Z0xyng6mZ6GHs=)
65. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEzrhkM8R83PgSGLZ05noUe0O49gcKzpJbCMP_kAG_GW2OsESvJm3OyPcuMnrRpNARC4eL2VSuq2vCxyNiKfAHvSLZKD5vv3azhsbtBjI1Rd-2kbO9y9Np2Rfz6oM1_yg==)
66. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEw-a2E06sYERu89O44yDlmgCDnoDVfyCDjGKN1Qr-8p1KgB0_H6r4Vhi0FUYPrjQRSMNZlgOGrgcTLQT8zTlOLAjzhIhYkw_-Jc_dLn-v9Y189aQ64ABT5QeSZPuvNqH3-jgQxnpVwdJyHFB1U3SgUFKRhW6XWQ48hsdvKsIkBUfXq8iGVHe6j0AM39X2Ur9NQkezHzjKJyE0eP80O0KEKT3KzFttbqiTtJBiKYtURrWIdI1MEr7SUBQ==)
67. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGR6f4Cjwh4rOp66Rt6B5R33tb4FmJ4R3Dyry6wX8-SE9tG2YtLvSuMcHAQXQqXK51U_8IDC_jrqoihog4utk1HIaRVxK-4CY2wtWfbz7Vr3JHbM14hKhDaiBynwP7rxBpcHbAcBbg9)
68. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGrdeT5UkBEAb42n8j6uDIVvbFHs5Tmz39XuBMmNiWAc4V9BG3tiCs7z6vepwuM52bW4WAMGyW--jzq4JtusYg2_RtTtt2tck1iuMps57Lxm4VzrcisF1yNjkI7GPMvZoAcah63cc8YD9e0cR6TNhG1xTD_53-md1LMosv0NhlR0UBBLdvrXFZOE5Bh-PSSh1gVm5PzwFEkjPnSpF5_RqUn9BmeniXUQH9WfdOTtQMs6_iYSHaAzD7_P0rI-Nr63dfYgPhlzSK2SJ4qlqP7DV21pQx_EcGFslCwgm3WSQ==)
69. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHBug2BQwl0rRV6YeXVb3MdWfJTI2c8xqMabiuMpXv_1R4tYW7nubxIcHjSaKiVyZcmZEtmJysDZq7VpyE3SM8NbTMoeLHAxerWvYLyRi0uoCJapmEEgFU7Y1QplMiT3w==)
70. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIAK8vXm4x6809G34T0bVZGMt4kpq-CdZNcdHXl51ey09RLzRLhUV1oCd1acvx7vEI6aVr7mi8JJX4aO6Cemd1cj1TBMUY-gA5iTJ8nCqch_-auzyBlSkgxfBvMlYHyQHrsXoJ7lNnEw==)
71. [bvsalud.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE5i4FfvfL0QMvHP4FnZkeQ5UWCdCHGsS1-X6fAhV4XwuOm_lGuf6qkbbjWm2y1TKowyL7GN1fJu79LjcmnW8TxJyMoyVxnnKBOiKVqdtSHHAFbODYHwPxV5m8b2oO3KWR6TjUORuWhsqIS57UnQIZflhFmm-pnjlYIXAo=)
72. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH_wqGSdqdiCwBkaWHTrTAAhYCwLl0fsHbh_o8v-DteqEAMjPs_5RhAbgr9whDF1sRTxWtmAMSxDmMo94Bdnmg9iaJs6BQPKHc6EflWhnf5j4nyN-huvpL_sTlLNKC6nQ==)
73. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFc_AF4vaJg0yQTRxDCFcIUpgOC-5QCnGr7SjF41f_OcwjlxOmj7VKVm7gc6wdueajUByc7FP3LgOxXxWY1EkKxRoQhTnwPHenXK0hVlK5n0t0rko6dOmimCF06rd4=)
74. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFnJat5mSbvL5CULshcUMNhfwmhqNiUdUSST2stvuWBXBhySiaEmoU-tb9w0NHxdGwopwJqqXBmZmc5_EQUlUTdXPSfNAoQatCHxvlFY6D1B1a5uG3XjuOSPg2wVMs=)
75. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEI8H0j-84P8FwWndxPImptQNFLx4BqYDaEn-bbPw_l6x_C55lABVHbq2j6PA5e6yAaoCCCOC1XfP9K5IUKmhtlx3ScZsUIttJtGn7bbvkuZZ98UIXDa27XFvhWwo52OjdQSNBmPw9R07pJp15GTEDRwsFe-thdA7gmRAHwi1j87PvL9e5klYwGFDwTo9U0xY2-eHvyNhNC53QM-dW04048a-ricwGNgg==)
76. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGml4RDErR6tiawFHjfp8LktbhJ_TeiWp230Y6NMkGTZBhb7p0nzu5ukFD44KxNu_sLX0pJtqdpZi7yDL5nWKwE_uff6b7LRAT_5m9PVToHqMbY4te0cK7SBVYUr-icEB1tSS3o8pJsFqTDb4dugLEc5CDfBSc4u5JpVo4pkGfUaSd4agF5Hcmm9t-pAr5W7g1dnTNLsuSPvrUuOiiaSQUImhdMDlt2BcpznnspbbqfagZkFG-sN3jO6ouJ8Sf-FlXK09pyFQ_luTcl8qw4IT81H4yAmasu9GeUUuFBuK-gUlh9ki7OO8U5XbdPrcC2uLblCH0=)
77. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH6m73PT8xtRquhhHLdvAfAq_2UTS8UUGvvRD4ocrx7qGfHaEp-vvhzMrMYuM18Of3WdkvceM7syAky3eG8Ec_X-puft_JngUduT7eVHkeU_Z-wyijlvRR9DSc4Nhr4Vq148_mlcfPL4Q==)
